$ALEC News
Last published 6d ago
- 6d agoALECAlector, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoALECAlector Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with...
- 6d agoALECAlector Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ)
- 3w agoALECAlector Announces Pricing of Underwritten OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (("Alector, NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of
- 4w agoALECAlector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration - ALECTOR INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Elector Pipeline Webinar, Advancing Next Generation Medicines for Neurodegeneration. At this time, all participants are in a listen-only mode. After the speaker's pr
- 1mo agoALECAlector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineGlobeNewswireAgenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) --
- 1mo agoALECAlector - 1773720 - ALECTOR INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som
- 1mo agoALECAlector - 1773720 - ALECTOR INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som
- 1mo agoALECMorgan Stanley 24th Annual Global Healthcare Conference - ALECTOR INCEarnings Call TranscriptsGood morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som
- 2mo agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative
- 3mo agoALECAlector Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s
- 6mo agoALECAlector Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's
- 6mo agoALECAlector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility AnalysisGlobeNewswire--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody
- 7mo agoALECBreaking Barriers: Alector Brain Carrier (ABC) Deep Dive & Fireside Chat with ALEC - CantorEarnings Call TranscriptsHello, everyone. I'm Pete Stavropoulos, a biotech analyst at Cantor with another webinar on the blood-brain barrier crossing technologies. It's an exciting time for the field. The blood- brain barrier has been a bottlene
- 8mo agoALECAlector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireAdvancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's
- 8mo agoALECAlector to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
- 11mo agoALECAlector Appoints Neil Berkley as Chief Financial Officer and Chief Business OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
- 11mo agoALECAlector to Participate in the Bank of America CNS Therapeutics ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireSelected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's
- 1y agoALECAlector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier ProgramsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector, Inc. (ALEC) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoALECAlector Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireOn track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial
- 1y agoALECAlector to Host Second Quarter and Mid-Year 2025 Earnings Conference CallGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector Provides Executive Leadership UpdateGlobeNewswire-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc.
- 1y agoALECAlector to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTopline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to
- 1y agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECGSKAlector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's DiseaseGlobeNewswire--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025
- 1y agoALECAlector Provides Executive Leadership UpdateGlobeNewswire--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc.
- 1y agoALECAlector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireTopline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants
- 1y agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector to Host Fourth Quarter and Full-Year 2024 Earnings Conference CallGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of
- 1y agoALECAlector Reports on Recent Progress and Outlines Strategic Priorities for 2025GlobeNewswireContinue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for
- 1y agoALECAlector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of
- 1y agoALECHTGCAlector Secures Flexible Credit Facility for Up to $50 Million From Hercules CapitalGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt
- 2y agoALECAlector Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireData from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a
- 2y agoALECGSKAlector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)GlobeNewswire--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)--
- 2y agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the
- 2y agoALECAlector, Inc. (ALEC) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoALECAlector Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireData from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study
- 2y agoALECAlector to Host Mid-Year Earnings Conference CallGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast
- 2y agoABBVALECAlector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)GlobeNewswire--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics
- 2y agoALECAlector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's
- 2y agoALECAlector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a
- 2y agoALECAlector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology PlatformGlobeNewswireSOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to
- 2y agoALECAlector to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a
- 2y agoALECAlector to Participate in Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the